A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients
PHASE1CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
August 1, 2013
Primary Completion Date
February 1, 2018
Study Completion Date
March 15, 2018
Conditions
Hematopoetic Stem Cell Transplant
Interventions
DRUG
Bortezomib administration
Trial Locations (2)
46202
Indiana University, Indianapolis
78229
Texas Transplant Institute, San Antonio
All Listed Sponsors
lead
Indiana University
OTHER
NCT01926899 - A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients | Biotech Hunter | Biotech Hunter